# A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

> **NCT05199584** · PHASE2 · COMPLETED · sponsor: **Endeavor Biomedicines, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumors With PTCH1 Loss-of-function Mutations

## Interventions

- **DRUG:** ENV-101 (taladegib)

## Key facts

- **NCT ID:** NCT05199584
- **Lead sponsor:** Endeavor Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-24
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199584, "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05199584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*